---
document_datetime: 2025-11-23 13:10:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet.html
document_name: qtrilmet.html
version: success
processing_time: 0.1075144
conversion_datetime: 2025-12-28 12:28:47.344156
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Qtrilmet

[RSS](/en/individual-human-medicine.xml/67247)

##### Withdrawn

This medicine's authorisation has been withdrawn

metformin hydrochloride / saxagliptin / dapagliflozin

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Qtrilmet](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 August 2020, the European Commission withdrew the marketing authorisation for Qtrilmet (metformin hydrochloride / saxagliptin / dapagliflozin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Qtrilmet was granted marketing authorisation in the EU on 11 November 2019 for the following indications in adults aged 18 years and older with type 2 diabetes mellitus:

- to improve glycaemic control when metformin, with or without sulphonylurea (SU), and either saxagliptin or dapagliflozin does not provide adequate glycaemic control
- when already being treated with metformin and saxagliptin and dapagliflozin.

The marketing authorisation was initially valid for a 5-year period. The product had not yet been marketed in the EU.

The European Public Assessment Report (EPAR) for Qtrilmet is updated to indicate that the marketing authorisation is no longer valid.

Qtrilmet : EPAR - Medicine overview

Reference Number: EMA/521799/2019

English (EN) (579.13 KB - PDF)

**First published:** 10/12/2019

**Last updated:** 09/10/2020

[View](/en/documents/overview/qtrilmet-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-552)

български (BG) (626.71 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/bg/documents/overview/qtrilmet-epar-medicine-overview_bg.pdf)

español (ES) (579.79 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/es/documents/overview/qtrilmet-epar-medicine-overview_es.pdf)

čeština (CS) (618.79 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/cs/documents/overview/qtrilmet-epar-medicine-overview_cs.pdf)

dansk (DA) (578.96 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/da/documents/overview/qtrilmet-epar-medicine-overview_da.pdf)

Deutsch (DE) (582.95 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/de/documents/overview/qtrilmet-epar-medicine-overview_de.pdf)

eesti keel (ET) (567.57 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/et/documents/overview/qtrilmet-epar-medicine-overview_et.pdf)

ελληνικά (EL) (625.56 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/el/documents/overview/qtrilmet-epar-medicine-overview_el.pdf)

français (FR) (580.79 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/fr/documents/overview/qtrilmet-epar-medicine-overview_fr.pdf)

hrvatski (HR) (602.92 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/hr/documents/overview/qtrilmet-epar-medicine-overview_hr.pdf)

italiano (IT) (578.63 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/it/documents/overview/qtrilmet-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (636.06 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/lv/documents/overview/qtrilmet-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (602.67 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/lt/documents/overview/qtrilmet-epar-medicine-overview_lt.pdf)

magyar (HU) (615.63 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/hu/documents/overview/qtrilmet-epar-medicine-overview_hu.pdf)

Malti (MT) (618.89 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/mt/documents/overview/qtrilmet-epar-medicine-overview_mt.pdf)

Nederlands (NL) (578.78 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/nl/documents/overview/qtrilmet-epar-medicine-overview_nl.pdf)

polski (PL) (620.12 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/pl/documents/overview/qtrilmet-epar-medicine-overview_pl.pdf)

português (PT) (580.04 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/pt/documents/overview/qtrilmet-epar-medicine-overview_pt.pdf)

română (RO) (601.67 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/ro/documents/overview/qtrilmet-epar-medicine-overview_ro.pdf)

slovenčina (SK) (618.69 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sk/documents/overview/qtrilmet-epar-medicine-overview_sk.pdf)

slovenščina (SL) (615.88 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sl/documents/overview/qtrilmet-epar-medicine-overview_sl.pdf)

Suomi (FI) (578.75 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/fi/documents/overview/qtrilmet-epar-medicine-overview_fi.pdf)

svenska (SV) (578.25 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sv/documents/overview/qtrilmet-epar-medicine-overview_sv.pdf)

Qtrilmet : EPAR - Risk-management-plan summary

English (EN) (610.53 KB - PDF)

**First published:** 10/12/2019

**Last updated:** 09/10/2020

[View](/en/documents/rmp-summary/qtrilmet-epar-risk-management-plan-summary_en.pdf)

## Product information

Qtrilmet : EPAR - Product information

English (EN) (782.76 KB - PDF)

**First published:** 10/12/2019

**Last updated:** 09/10/2020

[View](/en/documents/product-information/qtrilmet-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-420)

български (BG) (971.14 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/bg/documents/product-information/qtrilmet-epar-product-information_bg.pdf)

español (ES) (784.26 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/es/documents/product-information/qtrilmet-epar-product-information_es.pdf)

čeština (CS) (872.45 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/cs/documents/product-information/qtrilmet-epar-product-information_cs.pdf)

dansk (DA) (775.74 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/da/documents/product-information/qtrilmet-epar-product-information_da.pdf)

Deutsch (DE) (809.2 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/de/documents/product-information/qtrilmet-epar-product-information_de.pdf)

eesti keel (ET) (753.19 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/et/documents/product-information/qtrilmet-epar-product-information_et.pdf)

ελληνικά (EL) (929.34 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/el/documents/product-information/qtrilmet-epar-product-information_el.pdf)

français (FR) (808.14 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/fr/documents/product-information/qtrilmet-epar-product-information_fr.pdf)

hrvatski (HR) (761.11 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/hr/documents/product-information/qtrilmet-epar-product-information_hr.pdf)

íslenska (IS) (769.8 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/is/documents/product-information/qtrilmet-epar-product-information_is.pdf)

italiano (IT) (851.09 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/it/documents/product-information/qtrilmet-epar-product-information_it.pdf)

latviešu valoda (LV) (857.92 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/lv/documents/product-information/qtrilmet-epar-product-information_lv.pdf)

lietuvių kalba (LT) (785.86 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/lt/documents/product-information/qtrilmet-epar-product-information_lt.pdf)

magyar (HU) (880.68 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/hu/documents/product-information/qtrilmet-epar-product-information_hu.pdf)

Malti (MT) (902.28 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/mt/documents/product-information/qtrilmet-epar-product-information_mt.pdf)

Nederlands (NL) (805.75 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/nl/documents/product-information/qtrilmet-epar-product-information_nl.pdf)

norsk (NO) (756.66 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/no/documents/product-information/qtrilmet-epar-product-information_no.pdf)

polski (PL) (896.13 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/pl/documents/product-information/qtrilmet-epar-product-information_pl.pdf)

português (PT) (799.28 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/pt/documents/product-information/qtrilmet-epar-product-information_pt.pdf)

română (RO) (776.95 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/ro/documents/product-information/qtrilmet-epar-product-information_ro.pdf)

slovenčina (SK) (876.83 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sk/documents/product-information/qtrilmet-epar-product-information_sk.pdf)

slovenščina (SL) (851.59 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sl/documents/product-information/qtrilmet-epar-product-information_sl.pdf)

Suomi (FI) (767.12 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/fi/documents/product-information/qtrilmet-epar-product-information_fi.pdf)

svenska (SV) (763.56 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sv/documents/product-information/qtrilmet-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0003 14/08/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Qtrilmet : EPAR - All authorised presentations

English (EN) (506.63 KB - PDF)

**First published:** 10/12/2019

**Last updated:** 09/10/2020

[View](/en/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-903)

български (BG) (543.35 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/bg/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_bg.pdf)

español (ES) (503.81 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/es/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_es.pdf)

čeština (CS) (545.09 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/cs/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (502.07 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/da/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (502.67 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/de/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (506.91 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/et/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (550.23 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/el/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_el.pdf)

français (FR) (503.59 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/fr/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (558.01 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/hr/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (507.67 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/is/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_is.pdf)

italiano (IT) (500.4 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/it/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (550.5 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/lv/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (506.55 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/lt/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (534.93 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/hu/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (544.54 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/mt/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (497.07 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/nl/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (506.04 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/no/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_no.pdf)

polski (PL) (533.38 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/pl/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_pl.pdf)

português (PT) (519.42 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/pt/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_pt.pdf)

română (RO) (525.13 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/ro/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (528.03 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sk/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (539.17 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sl/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (516.21 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/fi/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (506.43 KB - PDF)

**First published:**

10/12/2019

**Last updated:**

09/10/2020

[View](/sv/documents/all-authorised-presentations/qtrilmet-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Qtrilmet Active substance

- metformin hydrochloride
- saxagliptin
- dapagliflozin

International non-proprietary name (INN) or common name

- metformin hydrochloride
- saxagliptin
- dapagliflozin

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Qtrilmet is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

- to improve glycaemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycaemic control.
- when already being treated with metformin and saxagliptin and dapagliflozin.

## Authorisation details

EMA product number EMEA/H/C/004910 Marketing authorisation holder

AstraZeneca AB

SE-151 85 Sodertalje

Opinion adopted 19/09/2019 Marketing authorisation issued 11/11/2019 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Qtrilmet : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (579.03 KB - PDF)

**First published:** 30/03/2020

**Last updated:** 09/10/2020

[View](/en/documents/procedural-steps-after/qtrilmet-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Qtrilmet : EPAR - Public assessment report

Adopted

Reference Number: EMA/524327/2019

English (EN) (2.58 MB - PDF)

**First published:** 10/12/2019

**Last updated:** 09/10/2020

[View](/en/documents/assessment-report/qtrilmet-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Qtrilmet

Adopted

Reference Number: EMA/CHMP/478963/2019

English (EN) (109.81 KB - PDF)

**First published:** 20/09/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-qtrilmet_en.pdf)

#### News on Qtrilmet

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019) 20/09/2019

**This page was last updated on** 09/10/2020

## Share this page

[Back to top](#main-content)